阿利西尤单抗对ST段抬高型心肌梗死PCI术后患者的血脂及机体炎性反应的影响  

Effect of Alicizumab on Blood Lipid and Inflammatory Response After PCI in Patients with ST Segment Elevation Myocardial Infarction

作　　者：卢金潮 林雪娇 LU Jinchao;LIN Xuejiao(Department of Cardiovascular Medicine,Xianyou County General Hospital,Putian,Fujian,351200,China)

机构地区：[1]福建省仙游县总医院心血管内科,福建莆田351200

出　　处：《中外医疗》2024年第32期117-120,共4页China & Foreign Medical Treatment

摘　　要：目的研讨阿利西尤单抗对ST段抬高型心肌梗死(ST-elevation myocardial infarction,STEMI)经皮冠脉介入术(percutaneous coronary intervention,PCI)术后的血脂及机体炎性反应的影响。方法随机选取2022年6月—2024年2月于福建省仙游县总医院行PCI术治疗的120例STEMI患者为研究对象,依据不同治疗方法分为两组,每组60例,对照组术后予以常规调脂,观察组在对照组基础上接受阿利西尤单抗治疗,比较两组血脂状况、机体炎性反应以及安全性。结果PCI术后1周及3个月,观察组3项血脂指标(总胆固醇、低密度脂蛋白胆固醇及甘油三酯)水平均低于对照组,差异有统计学意义(P均<0.05)。术后1周及3个月,观察组2项机体炎性指标(超敏C反应蛋白与白细胞介素-6)水平均低于对照组,差异有统计学意义(P均<0.05)。观察组中药物相关不良反应总发生率为5.00%(3/60),与对照组的8.33%(5/60)比较,差异无统计学意义(χ2=0.133,P=0.714)。结论阿利西尤单抗用于STEMI患者PCI术后可快速降低血脂水平、炎性因子水平,并保障用药安全。Objective To investigate the effect of alicizumab on blood lipid and inflammatory response after percutaneous coronary intervention(PCI)in patients with ST-elevation myocardial infarction(STEMI).Methods A total of 120 STEMI patients who underwent PCI in Xianyou County General Hospital of Fujian Province from June 2022 to February 2024 were randomly selected as the research objects.According to different treatment methods,they were divided into two groups,with 60 cases in each group.The control group was given routine lipid regulation after operation,and the observation group was treated with alicizumab on the basis of the control group.The blood lipid status,inflammatory response and safety of the two groups were compared.Results At 1 week and 3 months after PCI,the level of three blood lipid indexes(total cholesterol,low density lipoprotein cholesterol and triglyceride)in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).At 1 week and 3 months after PCI,the level of two inflammatory indexes(high-sensitivity C-reactive protein and interleukin-6)in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).The total incidence of drug-related adverse reactions in the observation group was 5.00%(3/60),which was similar to 8.33%(5/60)in the control group,and the difference was not statistically significant(χ2=0.133,P=0.714).Conclusion Alicizumab can quickly reduce blood lipid levels and inflammatory factor levels in STEMI patients after PCI,and ensure drug safety.

关 键 词：ST段抬高型心肌梗死 阿利西尤单抗 经皮冠脉介入术 血脂 炎性反应 

分 类 号：R54[医药卫生—心血管疾病]